David Roche of Quantum Strategy discusses the prospects of a renminbi-based international payment and reserve system, ...

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

A property transfer from a Catholic organization to La Roche University sets the college up for long-term growth, officials ...

FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

What was once a company town has been transformed into an idyllic resort community, featuring water views, hiking trails, and plenty of historic charm.

Fintel reports that on December 12, 2025, TD COWEN maintained coverage of Roche Holding (OTCPK:RHHBF) with a Hold recommendation. Analyst Price Forecast Suggests 32.36% Upside As of November 17, 2025, ...

Aurinia Pharmaceuticals posts record Lupkynis sales, addresses FDA queries with new data, and faces new competition from ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...